Clinical Trial Update: Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK) [Phase 1]

View source ↗

Summary

Phase 1 trial of subretinal injection of rAAV2-VMD2-hMERTK for retinal disease including retinitis pigmentosa has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Disease
• Retinitis Pigmentosa

Drugs mentioned

• rAAV2-VMD2-hMERTK (rAAV2-VMD2-hMERTK)

Snippet

Sponsor: King Khaled Eye Specialist Hospital | Conditions: Retinal Disease, Retinitis Pigmentosa | Phase 1 | Status: COMPLETED | Results posted: 2021-07-15